Scientific News Td Cowen Raises Boston Scientific Corporation Bsx Target To $115, Reaffirms ‘buy’ Rating Ahead Of Q4 Results
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Scientific News Td Cowen Raises Boston Scientific Corporation Bsx Target To $115, Reaffirms ‘buy’ Rating Ahead Of Q4 Results is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
Analyst Visit Confirms Growth Potential for Boston Scientific Corporation (BSX), Buy Rating Retained
Boston Scientific Corporation (NYSE:BSX) ranks among the best medical device stocks to invest in. Following an analyst visit to Boston Scientific Corporation (NYSE:BSX)’s headquarters, TD Cowen ... Read More
UBS Boosts Boston Scientific (BSX) Price Target After Strong Q3 Earnings
Boston Scientific Corporation (NYSE:BSX) ranks among the best long-term stocks to buy according to D. E. Shaw. On October 23, UBS maintained its Buy rating on Boston Scientific Corporation (NYSE:BSX) ... Read More
Boston Scientific Shares Surge on Exceptional Quarterly Performance
The medical technology sector is witnessing remarkable momentum as Boston Scientific delivers a stunning third-quarter report for 2025. While the financial r ... Read More
These Analysts Increase Their Forecasts On Boston Scientific After Upbeat Earnings
Boston Scientific Corporation (NYSE:BSX) reported better-than-expected third-quarter results on Wednesday. The company posted quarterly revenues of $5.07 billion on Wednesday, beating the consensus ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus